The MRC-PPU support teams and PIs have generated an impressive array of reagents for the study of the ubiquitylation system. This stimulated the establishment of the start-up company, Ubiquigent which exploits research and expertise based in the PPU. The company currently offers many reagents, kits and drug discovery services. Ubiquigent recently launched a successful deubiquitylase (DUB) profiling service that currently has over 30 enzymes on the panel, an E2 scan kit and a custom assay development service from which PPU receives royalties which are re-invested in our research programmes.



Ubiquigent have just announced £0.5million funding from IP Group plc and the Scottish Investment Bank, the investment arm of Scottish Enterprise. The investment will be used to accelerate the development and commercialisation of these drug discovery platforms. Ubiquigent has also announced the appointment of Mark Treherne to strengthen its board of directors. Mark has been active in the pharmaceutical industry for over 25 years. In this time, he has been involved in starting and raising over £140million for a number of early-stage biotechnology companies. Amongst these, Mark was a co-founder and Chief Executive of Cambridge Drug Discovery, which was acquired by BioFocus plc. Mark has served on the boards of over 14 private and public biopharmaceutical companies in both executive and non-executive roles.



For more information on Ubiquigent please click here.